Arima H, Miyaji T, Irie T, Hirayama F, Uekama K
Faculty of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Kumamoto 862, Japan.
Eur J Pharm Sci. 1998 Jan;6(1):53-9. doi: 10.1016/s0928-0987(97)00068-7.
The effect of hydroxypropyl-beta-cyclodextrin (HP-beta-CyD) on the cutaneous penetration and activation of ethyl 4-biphenylyl acetate (EBA), a prodrug of non-steroidal anti-inflammatory drug 4-biphenylylacetic acid (BPAA), from hydrophilic ointment was investigated, using hairless mouse skin in vitro. When the hydrophilic ointment containing a complex of EBA with HP-beta-CyD was applied to the full-thickness skin, HP-beta-CyD facilitated the penetration of EBA into the skin, the conversion of EBA to BPAA in the epidermis and the transfer of BPAA to the receptor phase. Under the present condition, pre- and post-application of the ointment containing HP-beta-CyD onto the skin did not affect the cutaneous penetration of EBA and its activation. When the ointment containing the EBA:HP-beta-CyD complex was applied to the skin, the flux of BPAA through the tape-stripped skin was greater than that through the full-thickness skin, while the activation of the prodrug in the skin was slowed down by the tape-stripping. When propylene glycol was used as a vehicle, HP-beta-CyD no longer enhanced the cutaneous permeation of BPAA through the full-thickness skin. These results suggest that the enhancing effect of HP-beta-CyD on the cutaneous penetration of EBA would be ascribable largely to an increase in effective concentration of EBA in the ointment. Furthermore, the slow diffusion of EBA solubilized in HP-beta-CyD through the stratum corneum, together with the vehicle effect, could make the prodrug more susceptible to the metabolic process that is active in the epidermis, eventually leading to the facilitated activation of the prodrug.
利用无毛小鼠皮肤在体外研究了羟丙基-β-环糊精(HP-β-CyD)对非甾体抗炎药4-联苯乙酸(BPAA)的前体药物乙酸4-联苯酯(EBA)从亲水性软膏中的皮肤渗透及活化的影响。当将含有EBA与HP-β-CyD复合物的亲水性软膏应用于全层皮肤时,HP-β-CyD促进了EBA向皮肤的渗透、EBA在表皮中向BPAA的转化以及BPAA向受体相的转移。在当前条件下,在皮肤上预先和后应用含有HP-β-CyD的软膏并不影响EBA的皮肤渗透及其活化。当将含有EBA:HP-β-CyD复合物的软膏应用于皮肤时,BPAA通过胶带剥离皮肤的通量大于通过全层皮肤的通量,而前体药物在皮肤中的活化因胶带剥离而减慢。当使用丙二醇作为载体时,HP-β-CyD不再增强BPAA通过全层皮肤的皮肤渗透。这些结果表明,HP-β-CyD对EBA皮肤渗透的增强作用在很大程度上可归因于软膏中EBA有效浓度的增加。此外,溶解在HP-β-CyD中的EBA通过角质层的缓慢扩散,连同载体效应,可使前体药物更容易受到表皮中活跃的代谢过程的影响,最终导致前体药物活化的促进。